Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013

Authors Raluy-Callado M, Lambrelli D, MacLachlan S, Khalid JM

Received 2 February 2015

Accepted for publication 9 April 2015

Published 13 May 2015 Volume 2015:10(1) Pages 925—937

DOI https://doi.org/10.2147/COPD.S82064

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Mireia Raluy-Callado,1 Dimitra Lambrelli,1 Sharon MacLachlan,1 Javaria Mona Khalid2

1Evidera, London, United Kingdom; 2Takeda Development Centre Europe Ltd, London, United Kingdom

Objectives: In 2013, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) updated the management strategy on COPD based on severity using a combined assessment of symptoms, degree of airflow limitation, and number of exacerbations. This study quantified prevalence and incidence of COPD in the United Kingdom and estimated disease severity by GOLD 2013 categories A/B (low risk) and C/D (high risk).
Methods: The Clinical Practice Research Datalink was used to identify COPD patients ≥40 years. Patient characteristics were described, and prevalence was calculated on December 31, 2013. Five-year incidence (2009–2013) was estimated, with rates standardized using 2011 UK population age and sex. To classify patients by GOLD categories, spirometry results, the modified British Medical Research Council grade, and history of exacerbations were used.
Results: The prevalent cohort comprised 49,286 patients with COPD with mean age 70 years; 51.0% were male. Overall prevalence was 33.3 per 1,000 persons (95% confidence interval [CI]: 33.1–33.6); 66.4% were classified as GOLD A/B and 33.6% as C/D. The standardized prevalence of GOLD A/B was 21.9 per 1,000 persons (95% CI: 21.7–22.1) and of C/D was 11.1 (95% CI: 10.9–11.2). A total of 27,224 newly diagnosed COPD patients were identified with mean age 67 years at diagnosis; 53.0% were male. Incidence was 2.2 per 1,000 person-years (95% CI: 2.2–2.3); 68.7% were classified in categories A/B and 31.3% in C/D, of which 17.2% did not receive COPD maintenance medication.
Conclusion: A third of COPD patients in the UK are considered high risk (GOLD 2013 categories C/D), and a third of patients are diagnosed for the first time at these severe stages. Given the progressive nature of the disease, results suggest that closer attention to respiratory symptoms for early detection, diagnosis, and appropriate treatment of COPD in the UK is warranted.

Keywords: COPD, prevalence, incidence, GOLD 2013, primary care management

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

COPD exacerbations by disease severity in England

Merinopoulou E, Raluy-Callado M, Ramagopalan S, MacLachlan S, Khalid JM

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:697-709

Published Date: 1 April 2016

A retrospective study to assess resource utilization in patients with cervical dystonia in the United Kingdom

Raluy-Callado M, Gabriel S, Dinet J, Wang M, Wasiak R

Neuropsychiatric Disease and Treatment 2015, 11:647-655

Published Date: 9 March 2015

Readers of this article also read:

COPD exacerbations by disease severity in England

Merinopoulou E, Raluy-Callado M, Ramagopalan S, MacLachlan S, Khalid JM

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:697-709

Published Date: 1 April 2016

Prevalence of chronic obstructive pulmonary disease in asymptomatic smokers

Sansores RH, Velázquez-Uncal M, Pérez-Bautista O, Villalba-Caloca J, Falfán-Valencia R, Ramírez-Venegas A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2357-2363

Published Date: 2 November 2015

Epidemiology of chronic obstructive pulmonary disease: a population-based study in Krasnoyarsk region, Russia

Artyukhov IP, Arshukova IL, Dobretsova EA, Dugina TA, Shulmin AV, Demko IV

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1781-1786

Published Date: 2 September 2015

Factors associated with inadequate diagnosis of COPD: On-Sint cohort analysis

Fernández-Villar A, López-Campos JL, Represas Represas C, Marín Barrera L, Leiro Fernández V, López Ramírez C, Casamor R

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:961-967

Published Date: 18 May 2015

Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes

Zhang JQ, Zhang JQ, Liu H, Zhao ZH, Fang LZ, Liu L, Fu WP, Shu JK, Feng JG, Dai LM

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:917-923

Published Date: 13 May 2015

Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COPD exacerbation requiring emergency department visits

Chang CH, Tsao KC, Hu HC, Huang CC, Kao KC, Chen NH, Yang CT, Tsai YH, Hsieh MJ

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:767-774

Published Date: 13 April 2015

Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:889-905

Published Date: 27 August 2014